Development of SARS-CoV-2 vaccines: should we focus on mucosal immunity?
Editorial Article
-
- Overview
-
- Research
-
- Identity
-
- Additional Document Info
-
- View All
-
Overview
publication date
funding provided via
published in
Research
keywords
-
COVID-19; intranasal vaccine; mucosal adjuvant; Oral vaccine; sIgA angiotensin converting enzyme 2; coroflu; influenza vaccine; Severe acute respiratory syndrome coronavirus 2 vaccine; unclassified drug; virus vaccine; drug research; Editorial; immune response; immunization; infection prevention; mucosal immunity; nonhuman; Severe acute respiratory syndrome coronavirus 2; vaccine immunogenicity
Identity
Digital Object Identifier (DOI)
PubMed ID
Additional Document Info
start page
end page
volume
issue